What is Exagen Inc.'s market cap?

Exagen Inc. (XGN) has a market capitalization of $106.3M and trades on NASDAQ.

What is Exagen Inc.'s revenue and profitability?

Exagen Inc. generated $68.4M in trailing twelve-month revenue with a net loss of $20.2M, representing a net margin of -29.5%. Gross margin stands at 58.3%, with free cash flow of -$27.6M. These figures are based on the Q1 2026 filing.

Who are Exagen Inc.'s competitors?

Exagen Inc.'s key competitors include Quest Diagnostics, Labcorp, Adicet Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Exagen Inc. partner with?

Exagen Inc.'s notable partners include Johns Hopkins University, Allegheny Health Network Research Institute, Werfen USA, LLC, and others.

Where is Exagen Inc. headquartered?

Exagen Inc. is headquartered in United States of America and employs approximately 179 people. It has been publicly traded since 2019.

Exagen Inc.

XGN

Market cap

$106.3M-43.7%

Revenue$68.4M+20.5%

Net income-$20.2M-30.0%

Free cash flow-$27.6M-96.9%

EPS (diluted)-$0.89-5.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$17.3MBeat by $897.4K EPS-$0.17Beat by $0.07

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$17.8M

EPS estimate-$0.19

Financials

Q1 2026

Income statement

See full

Revenue$17.3M+11.7%

Gross profit$10.2M+11.9%

Operating income-$3.4M-1.5%

Net income-$4.0M-5.7%

EPS (diluted)-$0.17+15.0%

Balance sheet

See full

Cash & equivalents$21.7M+90.6%

Total debt$27.1M+15.8%

Total equity$14.4M+125%

Total assets$52.0M+28.9%

Cash flow

See full

Operating cash flow-$10.4M+2.4%

CapEx$228.0K+102%

Free cash flow-$10.6M+1.3%

Valuation & ratios

Valuation

See full

Market cap$106.3M-43.7%

Enterprise value$111.74M-28.6%

P/S1.6×-1.2×

Profitability

See full

Gross margin58.3%-1.0pp

Operating margin-20.6%-2.9pp

Net margin-29.5%+2.5pp

Returns & leverage

See full

Return on equity-193.6%+355pp

Debt / equity1.9×-1.8×

Current ratio3.5×+1.1×

Segments

By segment

See full

Reportable Segment$17.3M+11.7%

Competitors

By market cap

Idexx Laboratories$43.9B-3.7%

Quest Diagnostics$25.6B+36.3%

Labcorp Holdings$24.7B+13.8%

Vor Biopharma$1.1B+248%

Avalo Therapeutics$1.0B+1,348%

Insight Molecular Diagnostics Inc.$151.8M+90.2%

Exagen Inc.$106.3M-34.2%

Adicet Bio, Inc.$75.3M+21.1%

By revenue growth

Exagen Inc.+20.5%

Idexx Laboratories+13.1%

Quest Diagnostics+9.9%

Labcorp Holdings+7.3%

Insight Molecular Diagnostics Inc.-49.3%

By net margin

Idexx Laboratories24.63%+1.9pp

Quest Diagnostics9.19%+0.2pp

Labcorp Holdings6.66%+1.1pp

Exagen Inc.-29.49%-2.2pp

Insight Molecular Diagnostics Inc.-2,454.64%-940pp

Avalo Therapeutics-7,965.76%—

Profile

Exagen Inc. is a medical technology company specializing in the development and commercialization of advanced diagnostic, prognostic, and monitoring tests for complex rheumatic and autoimmune diseases. The company's core value proposition lies in its proprietary AVISE brand, which utilizes innovative biomarkers and algorithmic interpretations to provide clinicians with greater diagnostic clarity for conditions like systemic lupus erythematosus and rheumatoid arthritis compared to traditional testing methods.

Competitive position

Exagen is a leader in rheumatology-focused diagnostics, holding a significant competitive advantage through its proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology and extensive patent protection.

GeographiesUnited States

Customer segmentsSpecialist physicians, Healthcare providers, Pharmaceutical companies

Business modelDirect-to-physician sales, Specialty laboratory services, B2B

SuppliersLaboratory equipment manufacturers, Reagent and chemical suppliers, Academic research institutions

CustomersRheumatology clinics, Health insurance payors, Pharmaceutical companies for clinical trials

CountryUnited States of America

Listed2019

Employees179.0

CEOJohn Aballi

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteexagen.com

FilingsSEC EDGAR

Ask your AI about Exagen Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exagen Inc.'s market cap?: Exagen Inc. (XGN) has a market capitalization of $106.3M and trades on NASDAQ.
What is Exagen Inc.'s revenue and profitability?: Exagen Inc. generated $68.4M in trailing twelve-month revenue with a net loss of $20.2M, representing a net margin of -29.5%. Gross margin stands at 58.3%, with free cash flow of -$27.6M. These figures are based on the Q1 2026 filing.
Who are Exagen Inc.'s competitors?: Exagen Inc.'s key competitors include Quest Diagnostics, Labcorp, Adicet Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Exagen Inc. partner with?: Exagen Inc.'s notable partners include Johns Hopkins University, Allegheny Health Network Research Institute, Werfen USA, LLC, and others.
Where is Exagen Inc. headquartered?: Exagen Inc. is headquartered in United States of America and employs approximately 179 people. It has been publicly traded since 2019.